4-(4,6-二吗啡啉-1,3,5-三嗪-2-基)苯胺 、 异氰酸对氟苯基酯 以65 mg (33% yield) of the title product was isolated as white solid的产率得到1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-(4-fluorophenyl)urea
参考文献:
名称:
Triazine compounds as PI3 kinase and MTOR inhibitors
TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS
申请人:WYETH LLC
公开号:US20170119778A1
公开(公告)日:2017-05-04
Compounds of formula I
wherein:
R
1
is
and R
2
, R
4
, and R
6-9
are defined herein, and pharmaceutically acceptable salts and esters thereof. These compounds inhibit PI3 kinase and mTOR, and may be used to treat diseases mediated by PI3 kinase and mTOR, such as a variety of cancers. Methods for making and using the compounds of this invention are disclosed. Various compositions containing the compounds of this invention are also disclosed.
[EN] TRIAZINE COMPOUNDS AS P13 KINASE AND MTOR INHIBITORS<br/>[FR] COMPOSÉS TRIAZINES EN TANT QU'INHIBITEURS DE KINASE P13 ET DE MTOR
申请人:WYETH CORP
公开号:WO2009143313A1
公开(公告)日:2009-11-26
Compounds of formula I (I) wherein: R1 is (II) or (III); and R2, R4, and R6-9 are defined herein, and pharmaceutically acceptable salts and esters thereof. These compounds inhibit PI3 kinase and mTOR, and may be used to treat diseases mediated by PI3 kinase and mTOR, such as a variety of cancers. Methods for making and using the compounds of this invention are disclosed. Various compositions containing the compounds of this invention are also disclosed.
[EN] TRIAZINE COMPOUNDS AS P13 KINASE AND MTOR INHIBITORS<br/>[FR] COMPOSÉS DE TRIAZINE FORMANT DES INHIBITEURS DE PI3-KINASE ET MTOR
申请人:WYETH CORP
公开号:WO2009143317A1
公开(公告)日:2009-11-26
Compounds of formula (I) wherein: R1 is and R2, R4, and R6-9 are defined herein, and pharmaceutically acceptable salts and esters thereof. These compounds inhibit PI3 kinase and mTOR, and may be used to treat diseases mediated by PI3 kinase and mTOR, such as a variety of cancers. Methods for making and using the compounds of this invention are disclosed. Various compositions containing the compounds of this invention are also disclosed.
Triazine compounds as PI3 kinase and mTOR inhibitors
申请人:Wyeth LLC
公开号:US08217036B2
公开(公告)日:2012-07-10
Compounds of formula I
wherein:
R1 is
and R2, R4, and R6-9 are defined herein, and pharmaceutically acceptable salts and esters thereof. These compounds inhibit PI3 kinase and mTOR, and may be used to treat diseases mediated by PI3 kinase and mTOR, such as a variety of cancers. Methods for making and using the compounds of this invention are disclosed. Various compositions containing the compounds of this invention are also disclosed.
Triazine compounds as P13 kinase and MTOR inhibitors
申请人:Wyeth LLC
公开号:US08748421B2
公开(公告)日:2014-06-10
Compounds of formula I
wherein:
R1 is
and R2, R4, and R6-9 are defined herein, and pharmaceutically acceptable salts and esters thereof. These compounds inhibit PI3 kinase and mTOR, and may be used to treat diseases mediated by PI3 kinase and mTOR, such as a variety of cancers. Methods for making and using the compounds of this invention are disclosed. Various compositions containing the compounds of this invention are also disclosed.